UnknownNot applicableNCT05600998

A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma

Studying Clear cell adenocarcinoma of the ovary

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Peking University Third Hospital
Principal Investigator
Hongyan Guo, Doctor
Peking University Third Hospital
Intervention
Camrelizumab(drug)
Enrollment
20 enrolled
Eligibility
18-75 years · All sexes
Timeline
2022 – 2024

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05600998 on ClinicalTrials.gov

Other trials for Clear cell adenocarcinoma of the ovary

Additional recruiting or active studies for the same condition.

See all trials for Clear cell adenocarcinoma of the ovary →

← Back to all trials